1. The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.
- Author
-
Qin C, Cao Q, Li P, Wang S, Wang J, Wang M, Chu H, Zhou L, Li X, Ye D, Zhang H, Huang Y, Dong B, Sun X, Zou Q, Cai H, Sun L, Zhu J, Liu F, Ji J, Cui L, Wang X, Zhou H, Zhao H, Wu B, Chen J, Jiang M, Zhang Z, Shao P, Ju X, and Yin C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Hand-Foot Syndrome genetics, Hand-Foot Syndrome mortality, Humans, Male, Middle Aged, Niacinamide administration & dosage, Niacinamide adverse effects, Phenylurea Compounds adverse effects, Sorafenib, Survival Rate, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell genetics, Carcinoma, Renal Cell mortality, Kidney Neoplasms drug therapy, Kidney Neoplasms genetics, Kidney Neoplasms mortality, Neoplasm Proteins genetics, Niacinamide analogs & derivatives, Phenylurea Compounds administration & dosage, Polymorphism, Genetic
- Abstract
The purpose of the present study was to investigate whether genetic variants that influence angiogenesis and sorafenib pharmacokinetics are associated with clinical outcomes and toxic effects in advanced renal cell carcinoma patients treated with this drug. One hundred patients with advanced renal cell carcinoma were enrolled. Forty-two polymorphisms in 15 genes were selected for genotyping and analyzed for associations with progression-free survival, overall survival, and toxic effects. We found that rs1570360 in VEGF and rs2239702 in VEGFR2 were significantly associated with progression-free. Specifically, patients carrying the variant genotypes (AG + AA) of these two polymorphisms both had an unfavorable progression-free. In addition, compared with those with the rs2239702 GG genotype, patients with the AG + AA genotype suffered an unfavorable OS. We found that the VEGF rs2010963 CG + GG genotypes had a significantly increased risk of hand-foot syndrome, and the ABCB1 rs1045642 CT + TT genotypes had an increased risk of high blood pressure. Our results suggest that polymorphisms in VEGF and VEGFR2 are associated with sorafenib clinical outcomes, and polymorphisms in VEGF and ABCB1 are associated with sorafenib-related toxicities. Larger studies are warranted to validate our findings.
- Published
- 2016
- Full Text
- View/download PDF